KR100889887B1 - 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도 - Google Patents

가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도 Download PDF

Info

Publication number
KR100889887B1
KR100889887B1 KR1020077017691A KR20077017691A KR100889887B1 KR 100889887 B1 KR100889887 B1 KR 100889887B1 KR 1020077017691 A KR1020077017691 A KR 1020077017691A KR 20077017691 A KR20077017691 A KR 20077017691A KR 100889887 B1 KR100889887 B1 KR 100889887B1
Authority
KR
South Korea
Prior art keywords
ctla4
cells
amino acid
ctla4 mutant
positive cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077017691A
Other languages
English (en)
Korean (ko)
Other versions
KR20070094019A (ko
Inventor
로버트 제이. 피치
죠세프 알. 나에무라
피터 에스. 린슬리
유르겐 바요라트
Original Assignee
브리스톨-마이어스스퀴브컴파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스스퀴브컴파니 filed Critical 브리스톨-마이어스스퀴브컴파니
Publication of KR20070094019A publication Critical patent/KR20070094019A/ko
Application granted granted Critical
Publication of KR100889887B1 publication Critical patent/KR100889887B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077017691A 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도 Expired - Lifetime KR100889887B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US09/579,927 2000-05-26
US21406500P 2000-06-26 2000-06-26
US60/214,065 2000-06-26
PCT/US2001/017139 WO2001092337A2 (en) 2000-05-26 2001-05-23 Soluble ctla4 mutant molecules and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020027015946A Division KR100895134B1 (ko) 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20070094019A KR20070094019A (ko) 2007-09-19
KR100889887B1 true KR100889887B1 (ko) 2009-03-24

Family

ID=26908652

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077017691A Expired - Lifetime KR100889887B1 (ko) 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도
KR1020027015946A Expired - Lifetime KR100895134B1 (ko) 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020027015946A Expired - Lifetime KR100895134B1 (ko) 2000-05-26 2001-05-23 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도

Country Status (41)

Country Link
EP (3) EP1536234B1 (enExample)
JP (1) JP4328525B2 (enExample)
KR (2) KR100889887B1 (enExample)
CN (2) CN101255192A (enExample)
AR (1) AR031699A1 (enExample)
AT (1) ATE271066T1 (enExample)
AU (2) AU6346601A (enExample)
BE (1) BE2011C041I2 (enExample)
BR (1) BRPI0111191B8 (enExample)
CA (1) CA2409748C (enExample)
CY (2) CY2011019I2 (enExample)
CZ (1) CZ304451B6 (enExample)
DE (2) DE60104282T2 (enExample)
DK (1) DK1248802T3 (enExample)
EC (1) ECSP024365A (enExample)
EE (2) EE05458B1 (enExample)
EG (1) EG24459A (enExample)
ES (2) ES2225549T3 (enExample)
FR (1) FR11C0053I2 (enExample)
GE (1) GEP20053658B (enExample)
HK (1) HK1048126B (enExample)
HU (2) HU228137B1 (enExample)
IL (1) IL152315A (enExample)
LT (1) LT5133B (enExample)
LU (1) LU91902I2 (enExample)
LV (1) LV12994B (enExample)
MX (1) MXPA02011534A (enExample)
MY (1) MY136113A (enExample)
NO (2) NO330797B1 (enExample)
PE (1) PE20011338A1 (enExample)
PL (1) PL206267B1 (enExample)
PT (1) PT1248802E (enExample)
RU (1) RU2283847C2 (enExample)
SI (1) SI1248802T1 (enExample)
SK (1) SK288131B6 (enExample)
TR (1) TR200402703T4 (enExample)
TW (2) TWI319405B (enExample)
UA (1) UA87432C2 (enExample)
UY (1) UY26723A1 (enExample)
WO (1) WO2001092337A2 (enExample)
ZA (1) ZA200208944B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HRP20030071B1 (hr) * 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
CA2482042A1 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
DE60335024D1 (de) * 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
KR101546441B1 (ko) 2006-12-20 2015-08-24 엠엠알글로벌, 인코포레이티드 항체 및 이들의 제조 및 사용 방법
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
BRPI0920749A8 (pt) * 2008-10-02 2017-12-12 Emergent Product Dev Seattle Proteínas de ligação de antagonista multialvo cd86
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
JP2014506482A (ja) 2011-02-23 2014-03-17 アムジエン・インコーポレーテツド Ｕｖｃ露光のための細胞培養培地およびそれに関連した方法
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
US9758566B2 (en) 2012-03-29 2017-09-12 The General Hospital Corporation Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
KR102133060B1 (ko) 2012-05-11 2020-07-10 메디뮨 리미티드 Ｃｔｌａ－４ 변이체
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
WO2014004857A1 (en) * 2012-06-27 2014-01-03 Orban Biotech Llc Ctla4 fusion proteins for the treatment of diabetes
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
AU2014376225C1 (en) 2014-01-13 2025-06-05 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN106687575B (zh) 2014-06-04 2021-04-30 美国安进公司 用于收获哺乳动物细胞培养物的方法
SI3227454T1 (sl) 2014-12-01 2020-06-30 Amgen Inc. Postopek za manipuliranje ravni vsebnosti glikana glikoproteina
WO2016130734A1 (en) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Use of phenolic antioxidants in cell culture for the production of proteins
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
DK3515489T3 (da) 2016-09-19 2026-01-26 Oncoc4 Inc Cd80- og cd86-bindende proteinsammensætinger og deres anvendelse
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
US12058986B2 (en) 2017-04-20 2024-08-13 Egenesis, Inc. Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
CN109453383A (zh) * 2018-11-12 2019-03-12 陈慧慧 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用
EP3887394A2 (en) 2018-11-30 2021-10-06 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
JP2022545917A (ja) 2019-08-27 2022-11-01 トニックス ファーマ リミテッド 修飾ｔｆｆ２ポリペプチド
EP3931303A1 (en) 2019-12-06 2022-01-05 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
BR112022024135A2 (pt) 2020-06-18 2022-12-27 Regeneron Pharma Metodologia de peptídeo pesado para medir com precisão lisina c-terminal não processada
CA3189533A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
CN118647416A (zh) 2021-12-16 2024-09-13 百时美施贵宝公司 用于病毒灭活的洗涤剂
AU2023228815A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033513A1 (en) * 1997-01-31 1998-08-06 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
HRP20030071B1 (hr) * 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033513A1 (en) * 1997-01-31 1998-08-06 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof

Also Published As

Publication number Publication date
NO20025656L (no) 2002-11-25
EP1248802B1 (en) 2004-07-14
ES2225549T3 (es) 2005-03-16
LT2002114A (en) 2003-12-29
PE20011338A1 (es) 2002-01-13
RU2283847C2 (ru) 2006-09-20
EP1536234A2 (en) 2005-06-01
ES2571852T3 (es) 2016-05-27
CN1309735C (zh) 2007-04-11
WO2001092337A3 (en) 2002-05-10
DE60104282T2 (de) 2005-10-13
TWI319405B (en) 2010-01-11
KR100895134B1 (ko) 2009-05-04
EE05557B1 (et) 2012-08-15
JP4328525B2 (ja) 2009-09-09
SI1248802T1 (en) 2005-02-28
FR11C0053I2 (fr) 2013-01-11
CY2011019I1 (el) 2016-12-14
AU6346601A (en) 2001-12-11
NO20025656D0 (no) 2002-11-25
HK1048126A1 (en) 2003-03-21
BRPI0111191B1 (pt) 2019-12-31
LT5133B (lt) 2004-05-25
NO2011027I2 (enExample) 2011-12-15
ATE271066T1 (de) 2004-07-15
UA87432C2 (uk) 2009-07-27
CN101255192A (zh) 2008-09-03
NO2011027I1 (no) 2012-01-09
MY136113A (en) 2008-08-29
LV12994B (en) 2003-08-20
IL152315A (en) 2010-04-15
CN1441810A (zh) 2003-09-10
CA2409748C (en) 2008-09-16
ZA200208944B (en) 2004-02-13
EE201100050A (et) 2011-10-17
KR20030009502A (ko) 2003-01-29
BE2011C041I2 (enExample) 2020-08-20
PL206267B1 (pl) 2010-07-30
HU228137B1 (en) 2012-12-28
SK288131B6 (sk) 2013-10-02
DK1248802T3 (da) 2004-11-15
BRPI0111191B8 (pt) 2021-05-25
PT1248802E (pt) 2004-11-30
CZ304451B6 (cs) 2014-05-14
AU2001263466C1 (en) 2006-10-26
CZ20023892A3 (cs) 2003-09-17
MXPA02011534A (es) 2004-08-12
AU2001263466B2 (en) 2006-04-27
EP1536234B1 (en) 2016-03-16
DE60104282D1 (de) 2004-08-19
EE05458B1 (et) 2011-08-15
TWI314933B (en) 2009-09-21
AR031699A1 (es) 2003-10-01
CA2409748A1 (en) 2001-12-06
ECSP024365A (es) 2003-03-31
EP3029062A1 (en) 2016-06-08
IL152315A0 (en) 2003-05-29
BR0111191A (pt) 2004-07-06
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
DE122011100063I1 (de) 2012-06-14
TR200402703T4 (tr) 2004-11-22
GEP20053658B (en) 2005-11-10
HUP0302201A3 (en) 2010-01-28
EE200200659A (et) 2004-06-15
HUS1300012I1 (hu) 2016-08-29
HK1048126B (en) 2005-03-04
NO330797B1 (no) 2011-07-18
EG24459A (en) 2009-07-16
EP1536234A3 (en) 2009-06-03
EP1248802B9 (en) 2005-05-11
EP1248802A2 (en) 2002-10-16
JP2004511213A (ja) 2004-04-15
UY26723A1 (es) 2001-12-28
FR11C0053I1 (enExample) 2012-01-13
CY1117625T1 (el) 2017-04-26
HK1071931A1 (en) 2005-08-05
HUP0302201A2 (hu) 2003-10-28
PL366231A1 (en) 2005-01-24
WO2001092337A2 (en) 2001-12-06
SK15702002A3 (sk) 2004-01-08
TW200906857A (en) 2009-02-16
CY2011019I2 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
KR100889887B1 (ko) 가용성 ｃｔｌａ4 돌연변이 분자 및 그의 용도
KR100864120B1 (ko) 가용성 ｃｔｌａ4 분자를 사용한 류마티스성 질환의 치료법
US20210115107A1 (en) Methods of treatment using ctla4 molecules
DK1536234T3 (en) SOLUBLE MUTANT CTLA4 MOLECULES AND APPLICATIONS THEREOF
HK1225393A1 (en) Soluble ctla4 mutant molecules and uses thereof
HK1071931B (en) Soluble ctla4 mutant molecules and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20070731

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070830

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071128

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20080630

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20081230

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090313

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090313

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20120222

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130221

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130221

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140221

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140221

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150224

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150224

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160218

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160218

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170220

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170220

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180219

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180219

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20200218

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20200218

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20210218

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20211123

Termination category: Expiration of duration